Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to -$19.3 million.

  • C4 Therapeutics' Net Cash Flow fell 4369.11% to -$19.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$840000.0, marking a year-over-year increase of 3698.42%. This contributed to the annual value of -$71.1 million for FY2024, which is 17328.97% down from last year.
  • According to the latest figures from Q3 2025, C4 Therapeutics' Net Cash Flow is -$19.3 million, which was down 4369.11% from $26.9 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Net Cash Flow ranged from a high of $184.9 million in Q2 2021 and a low of -$118.4 million during Q3 2021
  • Its 5-year average for Net Cash Flow is -$6.4 million, with a median of -$7.7 million in 2022.
  • Examining YoY changes over the last 5 years, C4 Therapeutics' Net Cash Flow showed a top increase of 44718.76% in 2021 and a maximum decrease of 42003.71% in 2021.
  • Quarter analysis of 5 years shows C4 Therapeutics' Net Cash Flow stood at -$84.6 million in 2021, then surged by 76.6% to -$19.8 million in 2022, then skyrocketed by 431.4% to $65.6 million in 2023, then plummeted by 106.33% to -$4.1 million in 2024, then tumbled by 366.22% to -$19.3 million in 2025.
  • Its Net Cash Flow stands at -$19.3 million for Q3 2025, versus $26.9 million for Q2 2025 and -$4.2 million for Q1 2025.